Description

103,752,000 equity shares of Re. 1/- each issued at premium of Re. 1/- on rights basis listed and permitted to trade with effect from October 10, 2025.

Summary

BSE has approved the listing of 103,752,000 new equity shares of STARLINEPS ENTERPRISES LIMITED (Scrip Code: 540492) issued on rights basis. The shares will be available for trading from October 10, 2025. These shares are issued at face value of Re. 1/- with a premium of Re. 1/- per share.

Key Points

  • Company: STARLINEPS ENTERPRISES LIMITED
  • Scrip Code: 540492
  • Number of new shares: 103,752,000 equity shares
  • Face value: Re. 1/- per share
  • Issue premium: Re. 1/- per share
  • Issue type: Rights basis
  • ISIN: INE594W01042
  • Distinctive Numbers: 259380001 to 363132000
  • Allotment date: October 7, 2025
  • Trading commencement: October 10, 2025
  • Ranking: Pari-passu with existing equity shares

Regulatory Changes

No regulatory changes. This is a routine listing notification for rights issue shares.

Compliance Requirements

  • Trading members must note the new securities are available for trading from October 10, 2025
  • The new shares carry the same rights and privileges as existing equity shares

Important Dates

  • Allotment Date: October 7, 2025
  • Trading Commencement: October 10, 2025 (Friday)

Impact Assessment

Market Impact: Medium - The rights issue results in dilution of existing shareholding by approximately 10.37 crore shares. The modest premium of Re. 1/- over face value suggests capital raising at relatively low cost.

Trading Impact: The new shares will increase the free float and trading volumes for STARLINEPS ENTERPRISES LIMITED. Existing shareholders who participated in the rights issue can now trade their allotted shares.

Investor Impact: Shareholders who did not participate in the rights issue will experience dilution in their ownership percentage. The pari-passu ranking ensures all shareholders maintain equal rights.

Impact Justification

Rights issue listing of significant number of shares (10.37 crores) affects existing shareholders but is routine corporate action with no market-wide impact